HomeAI · summaries
Storia in 9 fonti
Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks forward to a notable growth revival post-2028, actively pushing its obesity treatment initiatives.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Pfizer expands multibillion-dollar cost-cutting plan
Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.
- ·
cnbc.com
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
